CDKN2A and pancreatic neoplasm: It has been reported that p53 (~75%), KRAS (>90%), CDKN2A/p16 (>90%) and SMAD4/DPC4 (~50%) are frequently mutated in pancreatic cancer, and these mutations are tightly linked to its malignant behavior [6].